La cadena de opciones muestra datos clave de las opciones de acciones de Jasper Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Jasper Therapeutics..

Jasper Therapeutics (NASDAQ:JSPR) Bolsa, Cadena de Opciones

JASPER THERAPEUTICS INC

Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics Inc

Anthony Scaramucci believes Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is in the midst of a structural transformation, from a volatile tech-aligned investment to a maturing global asset more comparable <a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44932297/digital-gold-or-fools-gold-the-real-value-behind-bitcoin-in-2025#:~:text=In%20truth%2C%20Bitcoin%20isn't,stored%20with%20zero%20physical%20footprint.">to digital gold</a>.
What Happened: In an <a href="https://x.com/Cointelegraph/status/1922185336572010570">interview</a> with Bloomberg on Monday, the SkyBridge Capital founder said Bitcoin's growing adoption and long-term holding behavior are driving this evolution, dampening volatility and pushing it into the asset class category rather than a speculative investment.
"Ultimately, what we see is the evolution of Bitcoin from being sort of a tech asset tied to the Mag 7 or Nasdaq to something that's more akin to digital gold," Scaramucci said. 
As wallet growth accelerates, now estimated at over 300 million globally, he anticipates that broader adoption could lead to a billion holders, a milestone that would reduce price swings and reinforce Bitcoin's role in long-term portfolios.
He added that this cycle of increasing wallet distribution, institutional participation and reduced volatility could form a positive feedback loop, encouraging more large holders to enter the market.
The shift, he argued, prompts a key distinction: "Is Bitcoin an investment, or is it an asset class?" 
If the latter, he said, then valuations would shift from a market cap in the trillions, similar to tech stocks, to the levels of gold, which commands over $22 trillion in global value.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45352237/nakamoto-holdings-raises-710m-merges-with-kindlymd-to-build-bitcoin-treasury-holding-company">Nakamoto Holdings Raises $710M, Merges With KindlyMD To Build Bitcoin Treasury Holding Company</a>
Why It Matters: The remarks come as Bitcoin continues to consolidate above the $103,000 mark.
Bitfinex analysts report steady spot volume and neutral funding, with no immediate macro threats. 
Support lies near $98,500, while resistance stands between $104,000 and $106,000. 
In a note sent to Benzinga, the analysts caution that while momentum remains intact, Bitcoin may enter a consolidation phase, potentially delaying any new all-time highs until June as supply and demand stabilize above key psychological thresholds.
Medium-term conditions remain constructive. 
Bitcoin has outperformed equities and altcoins, and ETF inflows continue to show consistency. 
Barring any shocks from CPI data or central bank guidance, analysts see further upside in the months ahead.
Long-term, Bitfinex analysts echo Scaramucci's perspective, stating that Bitcoin is increasingly behaving like a macro reserve asset. 
Structural supply limitations, global ETF adoption, and a shift in U.S. regulatory tone have strengthened Bitcoin's fundamental outlook. 
Price targets between $150,000 and $180,000 for the current cycle remain in play, contingent on broader market stability.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45349057/strategy-buys-134b-in-bitcoin-at-99856-cites-155-btc-yield">Strategy Buys $1.34B In Bitcoin At $99,856, Cites 15.5% BTC Yield</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

Anthony Scaramucci Says Bitcoin Is Evolving From A Tech Asset To Digital Gold

WIIM

Bakkt Holdings, Inc. Class A Common Stock

BKKT

Bakkt Holdings shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Needham analyst Joshua Reilly reiterates Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) with a Buy and maintains $750 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Tyler Technologies, Maintains $750 Price Target

RLGT

Radiant Logistics shares are trading higher after the company reported better-than-expected Q3 financial results.

SNGX

Soligenix shares are trading lower after the company reported worse-than-expected Q1 EPS results.

D. Boral Capital analyst Jesse Sobelson maintains US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) with a Buy and maintains $3.5 price target.

USEG

D. Boral Capital Maintains Buy on US Energy, Maintains $3.5 Price Target

CHRS

Coherus BioSciences shares are trading lower. The company reported Q1 financial results.

VTSI

VirTra shares are trading higher after the company reported better-than-expected Q1 financial results.

Landstar also announced today that its Board of Directors declared a quarterly dividend of $0.40 per share payable on June 24, 2025, to stockholders of record as of the close of business on June 5, 2025. This quarterly dividend includes a $0.04 per share increase, or 11% over the amount of the Company's regular quarterly dividend declared following each of the prior three quarters.

Dividends

LSTR

Landstar System Boosts Quarterly Dividend By 11% To $0.40/Share

Nayax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) affirms FY2025 sales outlook from $410.00 million-$425.00 million to $410.00 million-$425.00 million vs $410.79 million estimate.

Guidance

NYAX

Nayax Affirms FY2025 Sales Guidance of $410.00M-$425.00M vs $410.79M Est

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Piper Sandler raised ZoomInfo Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) price target from $9 to $11. Piper Sandler analyst Brent Bracelin maintained a Neutral rating. ZoomInfo shares closed at $10.31 on Monday. <a href="https://www.benzinga.com/quote/ZI/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut the price target for Annexon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) from $16 to $11. Needham analyst Joseph Stringer maintained a Buy rating. Annexon shares closed at $1.77 on Monday. <a href="https://www.benzinga.com/quote/ANNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Compass Point slashed NexPoint Residential Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) price target from $50 to $42.5. Compass Point analyst Merrill Ross downgraded the stock from Buy to Neutral. NexPoint Residential Trust shares closed at $37.53 on Monday. <a href="https://www.benzinga.com/quote/NXRT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>DA Davidson lowered the price target for Rapid7, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from $29 to $21. DA Davidson analyst Rudy Kessinger downgraded the stock from Neutral to Underperform. Rapid7 shares closed at $26.74 on Monday. <a href="https://www.benzinga.com/quote/RPD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Benchmark slashed the price target for indie Semiconductor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) from $8 to $6. Benchmark analyst Cody Acree maintained a Buy rating. indie Semiconductor shares closed at $2.64 on Monday. <a href="https://www.benzinga.com/quote/INDI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) price target from $5 to $0.39. Leerink Partners analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. Affimed shares settled at $0.6930 on Monday. <a href="https://www.benzinga.com/quote/AFMD/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays increased Stanley Black &amp; Decker, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) price target from $69 to $90. Barclays analyst Julian Mitchell upgraded the stock from Equal-Weight to Overweight. Stanley Black &amp; Decker shares closed at $72.53 on Monday. <a href="https://www.benzinga.com/quote/SWK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut BILL Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) price target from $105 to $75. Canaccord Genuity analyst Joseph Vafi maintained a Buy rating. BILL Holdings shares closed at $47.37 on Monday.  <a href="https://www.benzinga.com/quote/BILL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased the price target for Matson, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MATX#NYSE">MATX</a>) from $125 to $135. Jefferies analyst Omar Nokta maintained a Buy rating. Matson shares settled at $113.94 on Monday. <a href="https://www.benzinga.com/quote/MATX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. slashed Neurogene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NGNE#NASDAQ">NGNE</a>) price target from $50 to $45. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Buy rating. Neurogene shares closed at $17.70 on Monday. <a href="https://www.benzinga.com/quote/NGNE/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying SWK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="586" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-1024x586.png" alt="" class="wp-image-913331" style="width:553px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-1024x586.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141-768x439.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/13075100/image-141.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45368490/under-armour-cyberark-software-and-3-stocks-to-watch-heading-into-tuesday">Under Armour, CyberArk Software And 3 Stocks To Watch Heading Into Tuesday</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

AFMD

ANNX

BILL

INDI

MATX

NGNE

NXRT

Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

D. Boral Capital analyst Jesse Sobelson maintains Microvision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) with a Buy and lowers the price target from $3 to $2.5.

MVIS

D. Boral Capital Maintains Buy on Microvision, Lowers Price Target to $2.5

ADAP

Adaptimmune Therapeutics shares are trading higher after the company reported better-than-expected Q1 financial results.

Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) with a Buy and maintains $4.25 price target.

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Earnings

Earnings Beats

Earnings Misses

Landstar System Q1 EPS $0.85 Misses $0.99 Estimate, Sales $1.15B Beat $1.13B Estimate

SGMO

Sangamo Therapeutics shares are trading lower after the company reported worse-than-expected Q1 financial results.

Bridgemarq Real Estate (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BRE#TSX">BRE</a>) reported quarterly earnings of $0.20 per share. This is a 5.26 percent increase over earnings of $0.19 per share from the same period last year. The company reported $77.97 million in sales this quarter. This is a 562.62 percent increase over sales of $11.77 million the same period last year.

TSX:BRE

Bridgemarq Real Estate Q1 Adj. EPS $0.20 Up From $0.19 YoY, Sales $77.97M Up From $11.77M YoY

ITOS

Trading Halt: Halted at 7:50:00 a.m. ET - Trading Halt: Halt News Pending

Palmer Luckey, the virtual-reality prodigy who sold Oculus to Facebook for $2 billion in 2014, says that payday granted him entry to an ultra-exclusive group chat called the "B Boys Club."
What Happened: The only password to the group chat is a unicorn-level exit: founders must have sold a company for at least $1 billion. "It's all boys who have sold a company for at least $1 billion," Luckey <a href="https://www.youtube.com/watch?v=21I_3VEs0iI">told</a> Peter Diamandis on the "Moonshots" podcast. While he insists women aren't barred, none are in the thread.
That omission is striking given deals like L'Oréal's $1.2 billion purchase of IT Cosmetics from co-founder Jamie Kern Lima in 2016.
By club standards, Instagram's Kevin Systrom and Mike Krieger (<a href="https://www.benzinga.com/news/15/10/5891968/instagrams-fifth-anniversary-how-good-of-a-deal-was-this-for-facebook">sold</a> to Facebook for $1 billion in 2012) would qualify easily. So would WhatsApp's Jan Koum and Brian Acton, who <a href="https://www.benzinga.com/news/14/02/4322191/update-facebook-announces-16b-cash-stock-merger-with-whatsapp">fetched</a> $19 billion two years later. Slack co-founder Stewart Butterfield dwarfs them all, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/12/18616683/6-salesforce-analysts-react-to-slack-deal-game-changer-potential">exiting</a> to Salesforce for $27.7 billion in 2021.
See also: <a href="https://www.benzinga.com/25/05/45370909/china-rejects-us-blame-for-fentanyl-crisis-calls-tariff-penalties-unreasonable-amid-easing-trade-tensions">China Rejects US Blame For Fentanyl Crisis, Calls Tariff Penalties Unreasonable Amid Easing Trade Tensions</a>
Some of the planet's richest men, however, are stuck on read. Meta chief Mark Zuckerberg, who&#8217;s worth roughly $226 billion by Bloomberg's latest count, never actually sold Facebook, so he's out, as are Bill Gates, Sam Altman and Warren Buffett.
What To Know: Luckey, now <a href="https://www.forbes.com/profile/palmer-luckey/">valued</a> by Forbes at about $2.5 billion thanks to defense-tech startup Anduril, spends his chat time "shaming" peers into using their fortunes for more than vintage race cars.
"Guys, you have so much money. Why are you not doing what you know is the right thing to do with this capital?" he recalled messaging.
Luckey believes founders should personally build the world they envision instead of outsourcing philanthropy. Some converts are redirecting cash; others, he concedes, still prefer the fast lane. "I'm not saying everyone should become a vigilante crime fighter, but why wouldn't you use your resources to do the thing that you know needs to be done?" Luckey said.
Image via Just dance/Shutterstock
Read next: <a href="https://www.benzinga.com/news/global/25/05/45369837/piers-morgan-tears-into-pakistani-expert-who-says-isi-didnt-know-osama-bin-laden-was-living-near-military-base-all-they-had-to-do-was-get-a-pair-of-binoculars">Piers Morgan Tears Into Pakistani Expert Who Says ISI &#8216;Didn&#8217;t Know&#8217; Osama Bin Laden Was Living Near Military Base: &#8216;All They Had To Do Was Get A Pair Of Binoculars&#8217;</a>

Tech

Oculus Founder Palmer Luckey Reveals He's In An Invite-Only Group Chat With Just One Entry Rule

Kohl's intends to use the net proceeds from the sale of the Notes in a series of transactions resulting in the repayment of borrowings under its revolving credit facility. Kohl's expects to borrow under its revolving credit facility to repay all of its 4.25% notes due 2025 at maturity.

Kohl's Plans $360M Senior Secured Notes Offering Due 2030, Cites Use Of Proceeds For Debt Repayment Strategy

Press Releases

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma

Jasper Therapeutics to Host Webinar to Present Preliminary Data from the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

Jasper Therapeutics Reports Positive Data from BEACON Study of Briquilimab in Chronic Spontaneous Urticaria

Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference

Health Care

Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics to Present at Upcoming March Investor Conferences

Jasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update

Jasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual Meeting

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting

Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Comments

Jasper Therapeutics

Jasper Therapeutics (JSPR) Opciones

Jasper Therapeutics (NASDAQ:JSPR) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL